Harvest Management’s Protalix BioTherapeutics PLX Stock Holding History

Harvest Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-1,000	Closed	-$49K	–	92
2013 Q2	$49K	Buy	+1,000	New	+$53.1K	0.07%	78

Other funds holding PLX

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Harvest Management's PLX Position: Q3 2013 in Review

Harvest Management sold out of Protalix BioTherapeutics (PLX) in Q3 2013, closing a stake of 1,000 shares — an estimated $49K sold.

Harvest Management first reported a position in PLX in Q2 2013 and held it in 1 quarter. The position peaked at $49K in Q2 2013. 47 funds tracked by Wall St. Rank hold PLX as of Q3 2013.

Harvest Management reported no remaining Protalix BioTherapeutics position as of Q3 2013 after selling out during the quarter.
Harvest Management sold 1,000 Protalix BioTherapeutics shares in Q3 2013, an estimated $49K.
Harvest Management first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 1 quarter.
Harvest Management's Protalix BioTherapeutics position peaked at $49K in Q2 2013.
47 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2013.

Based on Harvest Management's 13F filing for Q3 2013, filed 12 Nov 2013.